NBRVF (Nabriva Therapeutics) Net Margin %: -468.61% (As of Jun. 2023)


NBRVF Nabriva Therapeutics PLC NBRVF
12 GF Score
Price $0.00
View Full Analysis

What is Nabriva Therapeutics Net Margin %?

Nabriva Therapeutics NBRVF 12 Net Margin % is -468.61% as of Jun. 2023. GuruFocus rates NBRVF with a GF Score™ of 12/100.

Net margin is calculated as Net Income divided by its Revenue. Nabriva Therapeutics's Net Income for the three months ended in Jun. 2023 was $-12.06 Mil. Nabriva Therapeutics's Revenue for the three months ended in Jun. 2023 was $2.57 Mil. Therefore, Nabriva Therapeutics's net margin for the quarter that ended in Jun. 2023 was -468.61%.

The historical rank and industry rank for Nabriva Therapeutics's Net Margin % or its related term are showing as below:


NBRVF's Net Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -89.33
* Ranked among companies with meaningful Net Margin % only.

Nabriva Therapeutics  (OTCPK:NBRVF) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Nabriva Therapeutics Net Margin % Related Terms

Nabriva Therapeutics Net Margin % Historical Data

* Premium members only.

The historical data trend for Nabriva Therapeutics's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nabriva Therapeutics Net Margin % Chart

Nabriva Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,765.85 -1,068.20 -2,426.12 -181.69 -160.33

Nabriva Therapeutics Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -126.19 -131.08 -218.20 -114.62 -468.61

NBRVF vs BXRX, INM, ADTX: Net Margin % Comparison

For the Biotechnology subindustry, Nabriva Therapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nabriva Therapeutics Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nabriva Therapeutics's Net Margin % distribution charts can be found below:

* The bar in red indicates where Nabriva Therapeutics's Net Margin % falls into.


NBRVF
12GF Score
Nabriva Therapeutics PLC NBRVF
Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nabriva Therapeutics Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Nabriva Therapeutics's Net Margin for the fiscal year that ended in Dec. 2022 is calculated as

Net Margin=Net Income (A: Dec. 2022 )/Revenue (A: Dec. 2022 )
=-57.185/35.668
=-160.33 %

Nabriva Therapeutics's Net Margin for the quarter that ended in Jun. 2023 is calculated as

Net Margin=Net Income (Q: Jun. 2023 )/Revenue (Q: Jun. 2023 )
=-12.062/2.574
=-468.61 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of -468.61% mean?
Nabriva Therapeutics (NBRVF) has a Net Margin % of -468.61% as of Jun. 2023. Net margin is the ratio of total net income to net sales. View historical data on Nabriva Therapeutics and its competitors.
Is Nabriva Therapeutics' Net Margin % too high?
Nabriva Therapeutics' current Net Margin % is -468.61%. Overall, Nabriva Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Nabriva Therapeutics' Net Margin % compare to BXRX and INM?
Nabriva Therapeutics' Net Margin % of -468.61% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Nabriva Therapeutics and its competitors. Nabriva Therapeutics's current Net Margin % is -468.61%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nabriva Therapeutics stock overvalued right now?
Nabriva Therapeutics (NBRVF) has a current Net Margin % of -468.61%. The current Net Margin % is -468.61%. Nabriva Therapeutics' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Nabriva Therapeutics (NBRVF), the current Net Margin % is -468.61% as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nabriva Therapeutics Business Description

Address Alexandra House, Office 225/227, The Sweepstakes, Dublin, IRL, 4
Nabriva Therapeutics PLC is a clinical stage biopharmaceutical company. The company is engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The company has developed a product candidate, XENLETA, a semi-synthetic pleuromutilin antibiotic that is the first in its class for oral and IV administration in humans. The firm has commercial rights to two approved products, SIVEXTRO and XENLETA, as well as one development product candidate, CONTEPO.
12GF Score

Get the complete analysis for NBRVF

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price